Leerink Partnrs Issues Negative Forecast for SRPT Earnings

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) – Research analysts at Leerink Partnrs lowered their Q2 2025 EPS estimates for Sarepta Therapeutics in a report released on Wednesday, July 16th. Leerink Partnrs analyst J. Schwartz now expects that the biotechnology company will post earnings of $0.72 per share for the quarter, down from their previous estimate of $2.25. The consensus estimate for Sarepta Therapeutics’ current full-year earnings is $2.67 per share. Leerink Partnrs also issued estimates for Sarepta Therapeutics’ Q3 2025 earnings at $0.52 EPS, Q4 2025 earnings at ($0.20) EPS, FY2025 earnings at ($2.50) EPS, Q3 2026 earnings at $3.10 EPS, Q4 2026 earnings at $1.56 EPS and FY2026 earnings at $6.63 EPS.

Sarepta Therapeutics (NASDAQ:SRPT) last issued its quarterly earnings data on Tuesday, May 6th. The biotechnology company reported ($3.42) EPS for the quarter, missing the consensus estimate of $2.20 by ($5.62). The company had revenue of $744.86 million during the quarter, compared to the consensus estimate of $685.75 million. Sarepta Therapeutics had a negative return on equity of 14.88% and a negative net margin of 11.12%. The firm’s revenue for the quarter was up 80.2% compared to the same quarter last year. During the same quarter last year, the company posted $0.73 earnings per share.

Several other equities research analysts have also recently weighed in on the stock. JPMorgan Chase & Co. reduced their price target on shares of Sarepta Therapeutics from $28.00 to $20.00 and set an “overweight” rating on the stock in a research report on Monday. Wells Fargo & Company cut their price target on shares of Sarepta Therapeutics from $75.00 to $65.00 and set an “overweight” rating on the stock in a report on Thursday, July 17th. HC Wainwright reiterated a “sell” rating on shares of Sarepta Therapeutics in a report on Wednesday, June 25th. Morgan Stanley reiterated an “equal weight” rating and set a $40.00 price target (down from $113.00) on shares of Sarepta Therapeutics in a report on Monday, June 16th. Finally, Evercore ISI cut shares of Sarepta Therapeutics from an “outperform” rating to an “inline” rating and set a $50.00 price target on the stock. in a report on Thursday, May 8th. One analyst has rated the stock with a sell rating, seventeen have issued a hold rating and nine have assigned a buy rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Hold” and an average price target of $53.50.

Sarepta Therapeutics Trading Down 5.3%

SRPT opened at $13.32 on Monday. The company has a debt-to-equity ratio of 1.00, a current ratio of 4.02 and a quick ratio of 2.46. The company’s 50 day moving average is $28.42 and its 200 day moving average is $67.58. Sarepta Therapeutics has a 12-month low of $12.60 and a 12-month high of $150.48.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Byrne Asset Management LLC bought a new position in Sarepta Therapeutics during the first quarter worth about $30,000. Center for Financial Planning Inc. bought a new position in Sarepta Therapeutics during the first quarter worth about $31,000. Logan Capital Management Inc. bought a new position in Sarepta Therapeutics during the fourth quarter worth about $61,000. Ancora Advisors LLC grew its holdings in Sarepta Therapeutics by 150.0% during the first quarter. Ancora Advisors LLC now owns 500 shares of the biotechnology company’s stock worth $32,000 after purchasing an additional 300 shares during the period. Finally, Hurley Capital LLC bought a new position in Sarepta Therapeutics during the fourth quarter worth about $76,000. 86.68% of the stock is currently owned by institutional investors.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.